Home Blog of Signal Transduction DNA Damage/DNA Repair DNA/RNA Synthesis Y box binding protein 1 inhibition as a targeted therapy for ovarian cancer

Category

Archives

Popular Post

ESKM, a novel therapeutic agent for sensitive and resistant PH+ leukemias

The mechanism of resistance to JAK2 inhibitor in myeloproliferative neoplasms patients

Effects of PARP inhibitors in BRCA gene-mutated ovarian cancer

DASATINIB; An inhibitor of Receptor Tyrosine Kinase

GP130/JAK/STAT3 signaling pathway induces multiple myeloma

Y box binding protein 1 inhibition as a targeted therapy for ovarian cancer

Y box binding protein 1 (YB-1) is a multifunctional protein associated with tumor progression and the emergence of treatment resistance (TR). Here, we report an azopodophyllotoxin small molecule, SU056, that potently inhibits tumor growth and progression via YB-1 inhibition. This YB-1 inhibitor inhibits cell proliferation, resistance to apoptosis in ovarian cancer (OC) cells, and arrests in the G1 phase. Inhibitor treatment leads to enrichment of proteins associated with apoptosis and RNA degradation pathways while downregulating spliceosome pathway. In vivo, SU056 independently restrains OC progression and exerts a synergistic effect with paclitaxel to further reduce disease progression with no observable liver toxicity. Moreover, in vitro mechanistic studies showed delayed disease progression via inhibition of drug efflux and multidrug resistance 1, and significantly lower neurotoxicity as compared with etoposide. These data suggest that YB-1 inhibition may be an effective strategy to reduce OC progression, antagonize TR, and decrease patient mortality.

 

Comments:

That's fascinating! The discovery of SU056 as a potent inhibitor of Y box binding protein 1 (YB-1) sounds promising for combating tumor progression, particularly in ovarian cancer. The ability of SU056 to inhibit cell proliferation, promote apoptosis, and arrest cells in the G1 phase showcases its potential in impeding cancer growth.

The observed effects of SU056 on pathways related to apoptosis and RNA degradation while downregulating the spliceosome pathway indicate its multifaceted impact on cellular processes. Its effectiveness in inhibiting OC progression in vivo, both independently and in synergy with paclitaxel, without causing liver toxicity is a significant finding.

Additionally, the inhibition of drug efflux and multidrug resistance 1 by SU056, along with reduced neurotoxicity compared to etoposide, suggests its potential in overcoming treatment resistance and minimizing adverse effects commonly associated with chemotherapy.

The potential of YB-1 inhibition as a strategy to mitigate OC progression, counter treatment resistance, and potentially improve patient outcomes is exciting. Further research and clinical trials could validate its efficacy and safety, potentially offering a new avenue in cancer therapy.

Related Products

Cat.No. Product Name Information
E1331 SU056 SU056 is an inhibitor of Y box binding protein 1 (YB-1) with IC50 of 1.73 μM in Sk0V3 cells.

Related Targets

DNA/RNA Synthesis